newsfilter
← Latest News
Business Wire·

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 - - Second